Generation of mice expressing the human glucagon receptor with a direct replacement vector

Citation
Ll. Shiao et al., Generation of mice expressing the human glucagon receptor with a direct replacement vector, TRANSGEN RE, 8(4), 1999, pp. 295-302
Citations number
19
Categorie Soggetti
Molecular Biology & Genetics
Journal title
TRANSGENIC RESEARCH
ISSN journal
09628819 → ACNP
Volume
8
Issue
4
Year of publication
1999
Pages
295 - 302
Database
ISI
SICI code
0962-8819(199908)8:4<295:GOMETH>2.0.ZU;2-E
Abstract
The process of evaluating the in vivo efficacy of non-peptidyl receptor ant agonists in animal models is frequently complicated by failure of compounds displaying high affinity against the human receptors to show measurable af finity at the corresponding rodent receptors. In order to generate a suitab le animal model in which to evaluate the in vivo activity of non-peptidyl g lucagon receptor antagonists, we have utilized a direct targeting approach to replace the murine glucagon receptor with the human glucagon receptor ge ne by homologous recombination. Specific expression of the human glucagon r eceptor (GR) in the livers of transgenic mice was confirmed with an RNase p rotection assay, and the pharmacology of the human GRs expressed in the liv ers of these mice parallels that of human GR in a recombinant CHO cell line with respect to both binding of I-125-glucagon and the ability of glucagon to stimulate cAMP production. L-168,049, a non-peptidyl GR antagonist sele ctive for the human GR shows a 3.5 fold higher affinity for liver membrane preparations of human GR expressing mice (IC50 = 172 +/- 98 nM) in the pres ence of MgCl2 in marked contrast to the measured affinity of the murine rec eptor (IC50 = 611 +/- 97 nM) for this non-peptidyl antagonist. The human re ceptors expressed are functional as measured by the ability of glucagon to stimulate cAMP production and the selectivity of this antagonist for the hu man receptor is further verified by its ability to block glucagon-stimulate d cyclase activity with 5 fold higher potency (IC50 = 97.2 +/- 13.9 nM) tha n for the murine receptor (IC50 = 504 +/- 247 nM). Thus we have developed a novel animal model for evaluating GR antagonists in vivo. These mice offer the advantage that the regulatory sequences which direct tissue specific a nd temporal expression of the GR have been unaltered and thus expression of the human gene in these mice remains in the normal chromosomal context.